Alexander Muik

机构：BioNTech (Germany) · ORCID：0000-0003-4561-2273

发表论文 119 篇 · 总被引 8852 次 · h-index 35

代表论文

• Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects (2025 · Journal for ImmunoTherapy of Cancer · 被引 15)
• Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine (2024 · npj Vaccines · 被引 14)
• Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1 (2024 · Cell Reports · 被引 8)
• Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines (2025 · Nature Communications · 被引 4)
• Dose Selection for DuoBody ®‐ CD40x4 ‐ 1BB ( GEN1042 / BNT312 ) Using a mPBPK / RO Model Leveraging Preclinical and Clinical Data (2025 · Clinical Pharmacology & Therapeutics · 被引 3)
• Abstract 6061: Dual PD-L1 blockade and VEGF-A neutralization with the bispecific antibody BNT327/PM8002 shows potent antitumor activity in preclinical models (2025 · Cancer Research · 被引 3)